Cargando…

Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis

Umbilical cord platelet-rich plasma (C-PRP) has more growth factors and anti-inflammatory molecules compared with autologous PRP (A-PRP) derived from peripheral blood. The aim of this study was to compare intra-articular C-PRP or A-PRP injections in terms of safety and clinical efficacy for the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzotta, Alessandro, Pennello, Enrico, Stagni, Cesare, Del Piccolo, Nicolandrea, Boffa, Angelo, Cenacchi, Annarita, Buzzi, Marina, Filardo, Giuseppe, Dallari, Dante
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369463/
https://www.ncbi.nlm.nih.gov/pubmed/35956121
http://dx.doi.org/10.3390/jcm11154505
_version_ 1784766466493513728
author Mazzotta, Alessandro
Pennello, Enrico
Stagni, Cesare
Del Piccolo, Nicolandrea
Boffa, Angelo
Cenacchi, Annarita
Buzzi, Marina
Filardo, Giuseppe
Dallari, Dante
author_facet Mazzotta, Alessandro
Pennello, Enrico
Stagni, Cesare
Del Piccolo, Nicolandrea
Boffa, Angelo
Cenacchi, Annarita
Buzzi, Marina
Filardo, Giuseppe
Dallari, Dante
author_sort Mazzotta, Alessandro
collection PubMed
description Umbilical cord platelet-rich plasma (C-PRP) has more growth factors and anti-inflammatory molecules compared with autologous PRP (A-PRP) derived from peripheral blood. The aim of this study was to compare intra-articular C-PRP or A-PRP injections in terms of safety and clinical efficacy for the treatment of patients with hip osteoarthritis (OA). This study investigated the results of 100 patients with hip OA treated with three weekly ultrasound-guided injections of either C-PRP or A-PRP. Clinical evaluations were performed before the treatment and after two, six, and twelve months with the HHS, WOMAC, and VAS scores. No major adverse events were recorded. Overall, the improvement was limited with both treatments. Significant improvements in VAS (p = 0.031) and HHS (p = 0.011) were documented at two months for C-PRP. Patients with a low OA grade (Tonnis 1-2) showed a significantly higher HHS improvement with C-PRP than A-PRP at twelve months (p = 0.049). C-PRP injections are safe but offered only a short-term clinical improvement. The comparative analysis did not demonstrate benefits compared with A-PRP in the overall population, but the results are influenced by OA severity, with C-PRP showing more benefits when advanced OA cases were excluded. Further studies are needed to confirm the most suitable indications and potential of this biological injective approach.
format Online
Article
Text
id pubmed-9369463
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93694632022-08-12 Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis Mazzotta, Alessandro Pennello, Enrico Stagni, Cesare Del Piccolo, Nicolandrea Boffa, Angelo Cenacchi, Annarita Buzzi, Marina Filardo, Giuseppe Dallari, Dante J Clin Med Article Umbilical cord platelet-rich plasma (C-PRP) has more growth factors and anti-inflammatory molecules compared with autologous PRP (A-PRP) derived from peripheral blood. The aim of this study was to compare intra-articular C-PRP or A-PRP injections in terms of safety and clinical efficacy for the treatment of patients with hip osteoarthritis (OA). This study investigated the results of 100 patients with hip OA treated with three weekly ultrasound-guided injections of either C-PRP or A-PRP. Clinical evaluations were performed before the treatment and after two, six, and twelve months with the HHS, WOMAC, and VAS scores. No major adverse events were recorded. Overall, the improvement was limited with both treatments. Significant improvements in VAS (p = 0.031) and HHS (p = 0.011) were documented at two months for C-PRP. Patients with a low OA grade (Tonnis 1-2) showed a significantly higher HHS improvement with C-PRP than A-PRP at twelve months (p = 0.049). C-PRP injections are safe but offered only a short-term clinical improvement. The comparative analysis did not demonstrate benefits compared with A-PRP in the overall population, but the results are influenced by OA severity, with C-PRP showing more benefits when advanced OA cases were excluded. Further studies are needed to confirm the most suitable indications and potential of this biological injective approach. MDPI 2022-08-02 /pmc/articles/PMC9369463/ /pubmed/35956121 http://dx.doi.org/10.3390/jcm11154505 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mazzotta, Alessandro
Pennello, Enrico
Stagni, Cesare
Del Piccolo, Nicolandrea
Boffa, Angelo
Cenacchi, Annarita
Buzzi, Marina
Filardo, Giuseppe
Dallari, Dante
Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis
title Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis
title_full Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis
title_fullStr Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis
title_full_unstemmed Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis
title_short Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis
title_sort umbilical cord prp vs. autologous prp for the treatment of hip osteoarthritis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369463/
https://www.ncbi.nlm.nih.gov/pubmed/35956121
http://dx.doi.org/10.3390/jcm11154505
work_keys_str_mv AT mazzottaalessandro umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis
AT pennelloenrico umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis
AT stagnicesare umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis
AT delpiccolonicolandrea umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis
AT boffaangelo umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis
AT cenacchiannarita umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis
AT buzzimarina umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis
AT filardogiuseppe umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis
AT dallaridante umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis